Bavarian Nordic lands another vaccine contract for the US  

The Danish vaccine development company has been awarded a USD 40m contract for a freeze-dried version of its Imvamune smallpox vaccine
Danish vaccine development company Bavarian Nordic has been awarded yet another contract by the US government, this time for the development of a freeze-dried version of its Imvamune smallpox vaccine, reports the company in a press release on its website. The total prospective value of the order, placed by the Biomedical Advanced Research and Development Authority, is USD 40m.
Bavarian Nordic writes that a freeze-dried formulation of Imvamune has the advantage of a potentially increased shelf-life compared to the current liquid-frozen formulation, which would help overcome the challenges with the cold-chain logistics and storage.
With this new contract, the US government has so far awarded Imvamune development contracts to Bavarian Nordic worth more than USD 680 million.
“We are excited about receiving yet another contract from the US Government in support for the development of an advanced freeze-dried version of our Imvamune smallpox vaccine," says Anders Hedegaard, president & CEO of Bavarian Nordic, in the press release. "It clearly demonstrates the continued commitment from the US Government to support the development of advanced medical countermeasures.”
Headquartered in Denmark, Bavarian Nordic develops and produces innovative vaccines to prevent and treat life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefense, cancer and infectious diseases. Bavarian Nordic employs over 260 people and has operations in Germany, the US and Singapore. Bavarian Nordic's partners include Impfstoffwerk Dessau-Tornau (IDT) and Vaccine Solutions.
Link > Bavarian Nordic                                

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×